B-Cell Non-Hodgkin's Lymphoma: Epidemiology Forecast to 2033

Non-Hodgkin’s lymphoma (NHL) represents a group of cancers that develop in the lymphatic system. Individuals with NHL experience uncontrolled malignant white blood cells, rendering the immune system incapable of effectively fighting off infections. Among all malignant lymphomas, the 90% are composed of NHL, making it among the most prevalent hematological adult cancers (Ekströ Smedby et al., 2008).

NHL is segmented by its histology into B-cell, T-cell, and natural killer lymphocyte lymphoma, with B-cell lymphoma constituting 80─85% of the three subtypes. B-cell lymphoma is distinguished into further subtypes, each of which exhibits its own unique pathology and behavior. Among them, diffuse large B-cell lymphoma (DLBCL) is the most prevalent at 33-51% of cases, followed by follicular lymphoma (FL) at 18-51% of cases. Other common B-cell NHLs include marginal zone lymphoma (MZL) and mantle cell lymphoma (MCL), which compose 10-20% and 4-5% of cases, respectively. Each subtype is characterized by specific segmentations, including the distinction of DLBCL into germinal (GCB) and non-germinal center B-cell (non-GCB), as well as the subclassification of FL by histological features into grades 1,2, and 3 (Shustik et al., 2011; Singh et al., 2020).

Scope

This report provides an overview of the risk factors, comorbidities, and the global and historical epidemiological trends for B-cell NHL in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
The report includes a 10-year epidemiology forecast for the diagnosed incident and five-year prevalent cases of B-cell NHL. The diagnosed incident and five-year diagnosed prevalent cases of B-cell NHL are segmented by age (18 years and older), sex, and subtype (DLBCL, FL, MZL, and MCL). Furthermore, diagnosed incident and five-year diagnosed prevalent cases of each subtype are segmented by relevant subtype-specific clinical features, including the distinction between GCB and non-GCB DLBCL, FL grade, bulky and non-bulky disease among stage II FL and MCL cases, and Ann Arbor staging (stages I─IV) for all four subtypes. Finally, five-year diagnosed prevalent cases of all subtypes are segmented into cases that have relapsed and those that are in remission or active.

Reasons to Buy

The B-Cell Non-Hodgkin's Lymphoma Epidemiology series will allow you to:

Develop business strategies by understanding the trends shaping and driving the global B-cell NHL markets.
Quantify patient populations in the global B-cell NHL markets to improve product design, pricing, and launch plans.
Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for B-cell NHL therapeutics in each of the markets covered.
Understand magnitude of the B-cell NHL population by age, sex, histology, and subtype-specific stage at diagnosis.

1 B-Cell Non-Hodgkin’s Lymphoma: Executive Summary

1.1 Catalyst
1.2 Related reports
1.3 Upcoming reports

2 Epidemiology

2.1 Disease background
2.2 Risk factors and comorbidities
2.3 Global and historical trends
2.4 7MM forecast methodology
2.4.1 Sources
2.4.2 Forecast assumptions and methods
2.4.3 Forecast assumptions and methods: diagnosed incident cases of B-cell NHL - 7MM
2.4.4 Forecast assumptions and methods: diagnosed incident cases of diffuse large B-cell lymphoma, follicular lymphoma, marginal zone lymphoma, and mantle cell lymphoma
2.4.5 Forecast assumptions and methods: diagnosed incident cases of B-cell NHL by stage
2.4.6 Forecast assumptions and methods: five-year diagnosed prevalent cases of B-cell NHL
2.4.7 Forecast assumptions and methods: five-year diagnosed prevalent cases of diffuse large B-cell lymphoma, follicular lymphoma, marginal zone lymphoma, and mantle cell lymphoma
2.4.8 Forecast assumptions and methods: five-year diagnosed prevalent cases of B-cell NHL by stage
2.4.9 Forecast assumptions and methods: five-year diagnosed prevalent cases of diffuse large B-cell lymphoma, follicular lymphoma, marginal zone lymphoma, and mantle cell lymphoma that progress from local and regional to advanced stages
2.5 Epidemiological forecast for B-cell NHL (2023-33)
2.5.1 Diagnosed incident cases of B-cell NHL
2.5.2 Age-specific diagnosed incident cases of B-cell NHL
2.5.3 Sex-specific diagnosed incident cases of B-cell NHL
2.5.4 Diagnosed incident cases of B-cell NHL by subtype
2.5.5 Diagnosed incident cases of diffuse large B-cell lymphoma by Ann Arbor staging
2.5.6 Diagnosed incident cases of follicular lymphoma by Ann Arbor staging
2.5.7 Diagnosed incident cases of marginal zone lymphoma by Ann Arbor staging
2.5.8 Diagnosed incident cases of mantle cell lymphoma by Ann Arbor staging
2.5.9 Five-year diagnosed prevalent cases of B-cell NHL
2.5.10 Age-specific five-year diagnosed prevalent cases of B-cell NHL
2.5.11 Sex-specific five-year diagnosed prevalent cases of B-cell NHL
2.5.12 Five-year diagnosed prevalent cases of B-cell NHL by subtype
2.5.13 Five-year diagnosed prevalent cases of diffuse large B-cell lymphoma by Ann Arbor staging
2.5.14 Five-year diagnosed prevalent cases of follicular lymphoma by Ann Arbor staging
2.5.15 Five-year diagnosed prevalent cases of marginal zone lymphoma by Ann Arbor staging
2.5.16 Five-year diagnosed prevalent cases of mantle cell lymphoma by Ann Arbor staging
2.6 Discussion
2.6.1 Epidemiological forecast insight
2.6.2 Limitations of the analysis
2.6.3 Strengths of the analysis

3 Appendix

3.1 Bibliography
3.2 Primary market research - prescriber survey
3.3 About the Authors
3.3.1 Epidemiologist
3.3.2 Reviewers
3.3.3 Vice President of Disease Analysis and Intelligence
3.3.4 Global Head and EVP of Healthcare Operations and Strategy

List of Tables

Table 1: Summary of newly added data types
Table 2: Summary of updated data types
Table 3: B-cell NHL Lugano cancer stages
Table 4: B-cell NHL Ann Arbor cancer stages
Table 5: Risk factors and comorbidities for B-cell NHL
Table 6: High-prescribing physicians surveyed, by country

List of Figures

Figure 1: 7MM, diagnosed incident cases of B-cell NHL, both sexes, N, ages =18 years, 2023 and 2033
Figure 2: 7MM, five-year diagnosed prevalent cases of B-cell NHL, both sexes, N, ages =18 years, 2023 and 2033
Figure 3: 7MM, diagnosed incidence of B-cell NHL, both sexes, cases per 100,000 population, ages =18 years, 2023-33
Figure 4: 7MM, five-year diagnosed prevalence of B-cell NHL, both sexes, %, ages =18 years, 2023-33
Figure 5: 7MM, sources used to forecast the diagnosed incident cases of B-cell NHL
Figure 6: 7MM, sources used to forecast the diagnosed and five-year diagnosed prevalent cases of B-cell NHL
Figure 7: 7MM, sources used to forecast the diagnosed incident cases of B-cell NHL by histological subtype
Figure 8: 7MM, sources used to forecast the five-year diagnosed prevalent cases of B-cell NHL by histological subtype
Figure 9: 7MM, sources used to forecast the diagnosed incident cases of B-cell NHL by stage
Figure 10: 7MM, sources used to forecast the five-year diagnosed prevalent cases of B-cell NHL by stage
Figure 11: 7MM, diagnosed incident cases of B-cell NHL, N, both sexes, ages =18 years, 2023
Figure 12: 7MM, diagnosed incident cases of B-cell NHL by age, N, both sexes, 2023
Figure 13: 7MM, diagnosed incident cases of B-cell NHL by sex, N, ages =18 years, 2023
Figure 14: 7MM, diagnosed incident cases of B-cell NHL by subtype, N, both sexes, ages =18 years, 2023
Figure 15: 7MM, diagnosed incident cases of DLBCL by Ann Arbor staging, N, both sexes, ages =18 years, 2023
Figure 16: 7MM, diagnosed incident cases of FL by Ann Arbor staging, N, both sexes, ages =18 years, 2023
Figure 17: 7MM, diagnosed incident cases of MZL by Ann Arbor staging, N, both sexes, ages =18 years, 2023
Figure 18: 7MM, diagnosed incident cases of MCL by Ann Arbor staging, N, both sexes, ages =18 years, 2023
Figure 19: 7MM, five-year diagnosed prevalent cases of B-cell NHL, N, both sexes, ages =18 years, 2023
Figure 20: 7MM, five-year diagnosed cases of B-cell NHL by age, N, both sexes, 2023
Figure 21: 7MM, five-year diagnosed prevalent cases of B-cell NHL by sex, N, ages =18 years, 2023
Figure 22: 7MM, five-year diagnosed prevalent cases of B-cell NHL by subtype, N, both sexes, ages =18 years, 2023
Figure 23: 7MM, five-year diagnosed prevalent cases of DLBCL by Ann Arbor staging, N, both sexes, ages =18 years, 2023
Figure 24: 7MM, five-year diagnosed prevalent cases of FL by Ann Arbor staging, N, both sexes, ages =18 years, 2023
Figure 25: 7MM, five-year diagnosed prevalent cases of MZL by Ann Arbor staging, N, both sexes, ages =18 years, 2023
Figure 26: 7MM, five-year diagnosed prevalent cases of MCL by Ann Arbor staging, N, both sexes, ages =18 years, 2023

License	Format	Properties	Price
SINGLE USER LICENSE PDF	The product is a PDF.	This is a single user license, allowing one user access to the product.	€5345EUR$5,995USD£4,639GBP
SITE LICENSE PDF	The product is a PDF.	This is a site license, allowing all users within a given geographical location of your organization access to the product.	€10691EUR$11,990USD£9,278GBP
ENTERPRISE LICENSE PDF	The product is a PDF.	This is an enterprise license, allowing all employees within your organization access to the product.	€16036EUR$17,985USD£13,916GBP

Scope

Reasons to Buy

The B-Cell Non-Hodgkin's Lymphoma Epidemiology series will allow you to:

Table of Contents

Related Topics

Related Reports

Non Hodgkin Lymphoma (NHL) Market Report 2025

Non-Hodgkin Lymphoma Therapeutics - Global Strategic Business Report

CAR T-Cell Therapy for Non-Hodgkin's Lymphoma Market - A Global and Regional Analysis: Focus on Indication, Therapy, and Region - Analysis and Forecast, 2025-2035

Non-Hodgkin Lymphoma Treatment Market - Global Forecast 2025-2032

CAR T-Cell Therapy For Non-Hodgkin's Lymphoma- - Pipeline Insight, 2025